| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST14: Metreleptin for treating lipodystrophy |
|
Medicine details |
|
| Medicine name | metreleptin (Myalepta®) |
| Formulation | 3 mg powder for solution for injection, 5.8 mg powder for solution for injection, 11.3 mg powder for solution for injection |
| Reference number | 2022 |
| Indication | As an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients: with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above; with confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control |
| Company | Aegerion Pharmaceuticals Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/08/2018 |
| NICE guidance | |